Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of EGR1 binding sites in melanoma cells

ABSTRACT: We report the genome wide identification of EGR1 binding sites in the A375 melanoma cell line.

ORGANISM(S): Homo sapiens

PROVIDER: GSE116190 | GEO | 2018/09/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Identification of EGR1 binding sites in melanoma cells

Project description:Identification of EGR1 binding sites in melanoma cells

| PRJNA477660 | ENA

Identification of Androgen Receptor binding sites in hormone-depleted melanoma cells

Project description:We report the genome wide identification of AR binding sites in hormone-deprived A375 melanoma cell line, with either endogenous levels of the lncRNA SLNCR, or a vector expressing SLNCR1.

2018-09-01 | GSE116189 | GEO

Global analysis of in vivo EGR1-binding sites in erythroleukemia cell K562 using chromatin immunoprecipitation and massively parallel sequencing

Project description:Early growth response gene 1 (EGR1) has been implicated in megakaryocyte differentiation induced by PMA (phorbol 12-myristate 13-acetate). The identification of direct EGR1 target genes in global scale is critical for our understanding of how EGR1 contributes to this process. In this study, we provide a global survey on the binding location of EGR1 in the K562 cell treated by PMA using chromatin immunoprecipitation and massively parallel sequencing (ChIP-Seq). K562 is a human erythroleukemia cell line, which is situated in the common progenitor stage of megakaryocytic and erythroid lineages of the hematopoietic stem cell differentiation and its normally following differentiation is blockaded. Upon exposure to PMA stimuli, K562 cell can be induced into megakaryocytic cell, which provides a model for the study of transcriptional control networks. Over 14 000 highly confident in vivo EGR1 binding sites were identified in PMA treated K562 cell. More than 70% of these genomic sites associated with EGR1 binding were located around annotated gene regions. This whole genome study on the EGR1 targets may help a better understanding of the EGR1 regulated genes and the downstream pathway in megakaryocyte differentiation. The in vivo binding locations of EGR1 in K562 cell treated with PMA (phorbol 12-myristate 13-acetate, 10 ng/ml for 2 hours) were identified using chromatin immunoprecipitation combing with massively parallel sequencing (ChIP-Seq) based on AB SOLiD System 2.0.

2010-09-08 | E-GEOD-21665 | biostudies-arrayexpress

Global analysis of in vivo EGR1-binding sites in erythroleukemia cell K562 using chromatin immunoprecipitation and massively parallel sequencing

2010-09-08 | GSE21665 | GEO

Global identification of Androgen Receptor and EGR1 binding sites in melanoma reveals enriched co-binding at genes regulated by the lncRNA SLNCR

Project description:Global identification of Androgen Receptor and EGR1 binding sites in melanoma reveals enriched co-binding at genes regulated by the lncRNA SLNCR

| PRJNA477659 | ENA

NFATC2 knock-down on melanoma cell line A375

Project description:RNA-seq on NFATC2 knock-down (siRNA) on melanoma cell line A375

2017-09-29 | GSE99466 | GEO

EGR1 genomic binding in t-HESC cell line

Project description:EGR1 genomic binding in t-HESC cell line

| PRJNA591914 | ENA

A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation [human cell line ChIP-seq]

Project description:We report the distribution of H3K27Ac histone marks in multiple human melanoma cell lines with the aim of identifying super-enhancer regions and regions of interest. Also performed ChipSeq for H3K4Me1 to identify active enhancers in a representative human melanoma cell line, A375.

2016-02-01 | GSE75352 | GEO

Human A375 melanoma cell line treated with ciclopirox and crizotinib

Project description:To generate drug signatures in human A375 melanoma cell lines. A375 cell line was plated at 4 x 105 cells/mL overnight and treated with ciclopirox or crizotinib at 75% inhibitory concentrations (IC75, determined previously at 72h of treatment) or DMSO (vehicle) for 8h or 24h before harvest.

2018-01-01 | GSE59340 | GEO

Identification of Androgen Receptor binding sites in hormone-depleted melanoma cells

Project description:Identification of Androgen Receptor binding sites in hormone-depleted melanoma cells

| PRJNA477662 | ENA